BD Rx Inc., a subsidiary of BD, announced Tuesday that the U.S. Food and Drug Administration has approved the second drug to be offered in the company’s line of ready-to-administer prefilled generic injectables.
The product to launch is Metoclopramide Injection, USP, an injectable antiemetic.
Prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error, according to a company release. The company plans to launch 20 to 30 drugs in the line during the next few years.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy